SEC Form 4 · accession 0001104659-18-005845

Mersana Therapeutics, Inc. · MRSN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Vice President of Finance

Period of report

Jan 30, 2018

Accepted (ET)

Feb 1, 2018 · 4:01 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001442836

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Jan 30, 2018	M	889	$1.62	A	57,267	D
Common Stock	Jan 30, 2018	M	8,055	$1.53	A	65,322	D
Common Stock	Jan 30, 2018	M	3,262	$4.10	A	68,584	D
Common Stock	Jan 30, 2018	M	2,499	$6.98	A	71,083	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Option to Purchase Common Stock^F1	$1.62	Jan 30, 2018	M	889	D	—	Dec 15, 2024	Common Stock	889	889	D
Option to Purchase Common Stock^F2	$1.53	Jan 30, 2018	M	8,055	D	—	Jun 11, 2025	Common Stock	8,055	12,084	D
Option to Purchase Common Stock^F3	$4.10	Jan 30, 2018	M	3,262	D	—	Aug 29, 2026	Common Stock	3,262	8,155	D
Option to Purchase Common Stock^F4	$6.98	Jan 30, 2018	M	2,499	D	—	Mar 13, 2027	Common Stock	2,499	10,834	D

F1The original option grant for 3,555 option shares vests in equal quarterly installments over the first four years after the vesting commencement date, January 2, 2015.
F2The original option grant for 32,222 option shares vests in equal quarterly installments over the first four years after the vesting commencement date, June 12, 2015.
F3The original option grant for 13,047 option shares vests in equal quarterly installments over the first four years after the vesting commencement date, July 1, 2016.
F4The original option grant for 13,333 option shares vests in equal quarterly installments over the first four years after the vesting commencement date, March 14, 2017.